ArticleWorld journal of microbiology & biotechnology2026
Modulating 6 S RNA improves recombinant protein yield in Escherichia coli at lower temperatures.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-yield recombinant protein production in Escherichia coli requires balancing growth with proper folding at low temperatures. Here, we engineered 6 S RNA -a reversible σ⁷⁰ antagonist- as a modulator to enhance yields under cold stress (18 °C). Transcriptomic reanalysis of GSE74809 revealed growth phase-specific regulation: deletion of 6 S RNA upregulated amino acid biosynthesis during logarithmic growth but downregulated ribosomal and translation-related genes in the stationary phase. To test its functional impact, 6 S RNA and antisense constructs were cloned into pET‑24a(+), validated by RT‑qPCR, and evaluated at 18 °C and 37 °C. Both overexpression and knockdown impaired growth yet increased total protein levels (BCA, OD₆₀₀‑normalized). CFU enumeration confirmed reversible attenuation without toxicity, followed by asymmetric 18 h growth reduction: controls achieved 5.48‑fold expansion, whereas 6 S overexpression reached 2.39‑fold (44% of control) and anti‑6 S reached 2.95‑fold (67% of control). Critically, 6 S RNA overexpression at 18 °C boosted Cas9‑GFP mRNA fivefold and doubled functional GFP fluorescence.Overall, 6 S RNA enables tunable heterologous protein production by trading proliferation for enhanced folding capacity. Its targeted upregulation significantly improves recombinant protein yield under low‑temperature conditions, highlighting its potential for industrial bioprocessing.
Indexed as
Identifiers
42045731What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.